Theracryf Plc to Host Investor Webinar
Why we think this is neutral
This is a general update about an upcoming investor webinar, and does not contain any specific financial or operational news that would significantly impact the company's performance or outlook.
Key Points
- Theracryf plc to host investor webinar on 2 April 2025
- Webinar will focus on the company's Ox-1 addiction and SFX-01 glioblastoma programmes
- Recent fundraise will enable the company to advance the Orexin-1 antagonist to clinical trial readiness
Summary
The clinical stage therapeutics company is hosting an investor webinar to discuss its plans for its Ox-1 addiction and SFX-01 glioblastoma programmes.
Theracryf plc, the clinical stage drug development company focussing on oncology and neuropsychiatry, announces that it will be hosting an investor webinar on Wednesday, 2 April 2025 at 6.00 pm (BST). The webinar will focus on the Company's plans to drive its Ox-1 addiction and SFX-01 glioblastoma programmes, following the fundraise which completed earlier this month. These funds will enable the Company to take the Orexin-1 antagonist to the key inflection point of clinical trial readiness, allowing it to unlock potential commercial opportunities.
Key Dates
2 April 2025
Investor webinar
May 2025
More detailed presentation on Orexin-1 programme
GENERAL UPDATE